Zobrazeno 1 - 10
of 16
pro vyhledávání: '"C S, Crumpacker"'
Autor:
C S, Crumpacker
Publikováno v:
New England Journal of Medicine. 335:721-729
Autor:
A J, Japour, J J, Lertora, P M, Meehan, A, Erice, J D, Connor, B P, Griffith, P A, Clax, J, Holden-Wiltse, S, Hussey, M, Walesky, E, Cooney, R, Pollard, J, Timpone, C, McLaren, N, Johanneson, K, Wood, D, Booth, Y, Bassiakos, C S, Crumpacker
Publikováno v:
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association. 13(3)
A phase-I study was conducted to examine the safety, pharmacokinetics, and activity of combination 2',3'-dideoxyinosine (ddI) and ribavirin against human immunodeficiency virus type 1 (HIV-1)-positive individuals with CD4+ cell counts ofor = 500/micr
Autor:
R W, Coombs, S L, Welles, C, Hooper, P S, Reichelderfer, R T, D'Aquila, A J, Japour, V A, Johnson, D R, Kuritzkes, D D, Richman, S, Kwok, J, Todd, J B, Jackson, V, DeGruttola, C S, Crumpacker, J, Kahn
Publikováno v:
The Journal of infectious diseases. 174(4)
Human immunodeficiency virus (HIV)-1 RNA level in plasma was evaluated as a surrogate marker for disease progression in a clinical trial of advanced HIV-1 infection. Baseline HIV-1 RNA level was an independent predictor of disease progression (relati
Autor:
S L, Welles, J B, Jackson, B, Yen-Lieberman, L, Demeter, A J, Japour, L M, Smeaton, V A, Johnson, D R, Kuritzkes, R T, D'Aquila, P A, Reichelderfer, D D, Richman, R, Reichman, M, Fischl, R, Dolin, R W, Coombs, J O, Kahn, C, McLaren, J, Todd, S, Kwok, C S, Crumpacker
Publikováno v:
The Journal of infectious diseases. 174(4)
The association of plasma human immunodeficiency virus type 1 (HIV-1) RNA level at study entry and over time with clinical progression was evaluated in 187 patients from AIDS Clinical Trials Group protocol 116A who had little or no prior zidovudine t
Autor:
A J, Japour, S, Welles, R T, D'Aquila, V A, Johnson, D D, Richman, R W, Coombs, P S, Reichelderfer, J O, Kahn, C S, Crumpacker, D R, Kuritzkes
Publikováno v:
The Journal of infectious diseases. 171(5)
Zidovudine resistance mutations at reverse transcriptase codons 215 or 41 were found in two-thirds of human immunodeficiency virus type 1 (HIV-1) isolates obtained at baseline from patients enrolled in an AIDS Clinical Trials Group (ACTG) protocol th
Autor:
R T, D'Aquila, V A, Johnson, S L, Welles, A J, Japour, D R, Kuritzkes, V, DeGruttola, P S, Reichelderfer, R W, Coombs, C S, Crumpacker, J O, Kahn, D D, Richman
Publikováno v:
Annals of internal medicine. 122(6)
To evaluate the association between resistance of human immunodeficiency virus type 1 (HIV-1) to zidovudine and clinical progression.Retrospective analysis of specimens from patients in the AIDS Clinical Trials Group (ACTG) protocol 116B/117, a rando
Publikováno v:
The Journal of infectious diseases. 169(6)
Questions have arisen regarding the clinical outcome and the possible selection of resistant virus when patients with genital herpes discontinue prolonged chronic acyclovir; 239 immunocompetent patients with a history of frequently recurring genital
Autor:
J O, Kahn, S W, Lagakos, D D, Richman, A, Cross, C, Pettinelli, S H, Liou, M, Brown, P A, Volberding, C S, Crumpacker, G, Beall
Publikováno v:
The New England journal of medicine. 327(9)
Although zidovudine is effective in patients with human immunodeficiency virus (HIV) infection, its efficacy may decline with prolonged use. Didanosine is another inhibitor of HIV reverse transcriptase. We evaluated the effectiveness of changing anti
Autor:
B J, Dezube, A B, Pardee, L A, Beckett, C M, Ahlers, L, Ecto, J, Allen-Ryan, A, Anisowicz, R, Sager, C S, Crumpacker
Publikováno v:
Journal of acquired immune deficiency syndromes. 5(11)
The human immunodeficiency virus establishes an intimate interaction with the immune system. The virus can use cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (Il-1), to regulate its own expression by modifying the normal
Autor:
C S, Crumpacker, M, Heath-Chiozzi
Publikováno v:
Journal of acquired immune deficiency syndromes. 4